[go: up one dir, main page]

ATE479667T1 - Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis - Google Patents

Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis

Info

Publication number
ATE479667T1
ATE479667T1 AT04709122T AT04709122T ATE479667T1 AT E479667 T1 ATE479667 T1 AT E479667T1 AT 04709122 T AT04709122 T AT 04709122T AT 04709122 T AT04709122 T AT 04709122T AT E479667 T1 ATE479667 T1 AT E479667T1
Authority
AT
Austria
Prior art keywords
sup
thiazolyl
based compounds
kinase inhibitors
kinase
Prior art date
Application number
AT04709122T
Other languages
English (en)
Inventor
John Hynes
Hong Wu
Katerina Leftheris
Chunjian Liu
Jagabandhu Das
Robert Moquin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE479667T1 publication Critical patent/ATE479667T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04709122T 2003-02-06 2004-02-06 Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis ATE479667T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44541003P 2003-02-06 2003-02-06
PCT/US2004/003879 WO2004071440A2 (en) 2003-02-06 2004-02-06 Thiazolyl-based compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE479667T1 true ATE479667T1 (de) 2010-09-15

Family

ID=32869361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709122T ATE479667T1 (de) 2003-02-06 2004-02-06 Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis

Country Status (6)

Country Link
US (2) US7169771B2 (de)
EP (1) EP1594854B1 (de)
AT (1) ATE479667T1 (de)
DE (1) DE602004028907D1 (de)
ES (1) ES2349532T3 (de)
WO (1) WO2004071440A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517234A (ja) * 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
US7396935B2 (en) 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
US20080125432A1 (en) * 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
MX2007008973A (es) * 2005-01-26 2007-09-18 Irm Llc Composiciones y compuestos como inhibidores de cinasa de proteina.
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
KR101142283B1 (ko) * 2005-03-11 2012-05-07 스미또모 가가꾸 가부시끼가이샤 2-아미노티아졸 카르복사미드 유도체의 신규한 제조방법
TWI366561B (en) 2005-06-21 2012-06-21 Mitsui Chemicals Inc Amide derivative and insecticide containing the same
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
US20100022541A1 (en) * 2006-09-25 2010-01-28 Sonia Escaich Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
JP2010508288A (ja) 2006-10-27 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
WO2008079873A2 (en) * 2006-12-20 2008-07-03 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2009054468A1 (ja) 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
RU2495430C1 (ru) * 2012-03-29 2013-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки эффективности терапии хронического миелолейкоза
RU2495427C1 (ru) * 2012-07-04 2013-10-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования ответа на химиотерапию при хроническом лимфолейкозе
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (de) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase
AU2019265268C1 (en) * 2018-05-09 2022-08-04 Lg Chem, Ltd. Novel compound exhibiting enteropeptidase inhibitory activity
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
PL196955B1 (pl) 1998-12-04 2008-02-29 Bristol Myers Squibb Co Pochodna 3-podstawionego -4-arylochinolin -2-onu jako modulator kanałów potasowych, jej zastosowanie i kompozycja farmaceutyczna
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
EP1205478A4 (de) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd INHIBITOREN DER p38MAP-KINASE
SE9904177D0 (sv) 1999-11-18 1999-11-18 Astra Ab Novel compounds
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1392684B1 (de) 2001-06-01 2006-09-13 Vertex Pharmaceuticals Incorporated Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
PL368035A1 (en) 2001-08-31 2005-03-21 Bristol-Myers Squibb Company Compositions and methods for the treatment of cancer
AU2002357137A1 (en) 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase

Also Published As

Publication number Publication date
EP1594854A2 (de) 2005-11-16
EP1594854B1 (de) 2010-09-01
US7323482B2 (en) 2008-01-29
WO2004071440A2 (en) 2004-08-26
DE602004028907D1 (de) 2010-10-14
US20070093537A1 (en) 2007-04-26
US7169771B2 (en) 2007-01-30
WO2004071440A3 (en) 2004-12-09
EP1594854A4 (de) 2007-07-18
US20040220233A1 (en) 2004-11-04
ES2349532T3 (es) 2011-01-04

Similar Documents

Publication Publication Date Title
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
ATE482200T1 (de) Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
ATE338461T1 (de) Pyrazolpyrimidinfungizide
NO20062185L (no) Hepatitt C virus-inhibitorer
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20062267L (no) Hepatitt C virus inhibitorer
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
NO20062339L (no) Hepatitt C virus-inhibitoerer
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
DE602004014628D1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
DE602005025332D1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü-(phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DE60325984D1 (de) 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
EA200300458A1 (ru) Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
DE502004009016D1 (de) Verwendung von chinaldin-und naphthalinderivaten als kristallisationsmodifikatoren
ATE449760T1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties